CSIMarket Company Name, Ticker, Customers, else..
 
Xortx Therapeutics inc   (NASDAQ: XRTX)
 
Price: $2.3100 $-0.01 -0.431%
Day's High: $2.309999942779541 Week Perf: 4.15 %
Day's Low: $ 2.31 30 Day Perf: 8.45 %
Volume (M): 740 52 Wk High: $ 7.05
Volume (M$): $ 0 52 Wk Avg: $2.71
Open: $2.31 52 Wk Low: $1.73



 Market Capitalization (Millions $) 11
 Shares Outstanding (Millions) 5
 Employees 15
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) 0
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Business Description


Xortx Therapeutics Inc is a biopharmaceutical company that focuses on the development and commercialization of innovative therapies for the treatment of kidney diseases. The company is dedicated to improving the quality of life for patients with kidney-related conditions by developing novel drugs that target the underlying causes of these diseases. Xortx Therapeutics is known for its expertise in the field of renal biology and is committed to advancing the standard of care for kidney disease patients through its research and development efforts.


   Company Address: 3710 — 33rd Street NW Calgary 0 AB
   Company Phone Number: 455-7727   Stock Exchange / Ticker: NASDAQ XRTX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMRX   -1.23%    
BHC   -2.01%    
GRFS   -3.93%    
TEVA   -5.7%    
UTHR   -0.48%    
VTRS        0.72% 
• View Complete Report
   



Product Service News

In a strategic move that could lead to significant advances in gout treatment, XORTX Therapeutics Inc. (NAS...

Published Wed, Sep 3 2025 12:01 PM UTC

Title : XORTX Therapeutics Begins IND Preparation for XORLO in Gout Program Amid Market FluctuationsIn a strategic move that could lead to significant advances in gout treatment, XORTX Therapeutics Inc. (NASDAQ: XRTX) has officially initiated the preparation of an Investigational New Drug (IND) application for XORLO, a promising candidate in its gout program. This developmen...
Product Service News

Navigating Growth XORTX’s Strategic Leap Toward Gout Treatment Approval,

Published Wed, Mar 19 2025 12:09 PM UTC

Accelerating Pathways: XORTX’s Strategic Developments in Gout Treatment In recent developments within the biotechnology sector, XORTX Therapeutics Inc. has captured attention with its ongoing strides towards advancing its novel drug, XRx-026, designed to treat gout. Garnering interest due to its recent interaction with the U.S. Food and Drug Administration (FDA), XORTX hop...
Management Announcement

XORTX Therapeutics Faces Financial Headwinds as it Shifts Focus on Gout Treatment Amid Leadership Changes

Published Mon, Jan 6 2025 12:00 PM UTC

XORTX Therapeutics Faces Financial Headwinds as it Shifts Focus on Gout Treatment Amid Leadership ChangesIn an era marked by relentless innovation in biopharmaceuticals, XORTX Therapeutics Inc. appears to be navigating a tumultuous path. Recently, the Calgary-based company announced plans to advance its late-stage gout program aimed at patients intolerant to allopurinol, an ...
Management Announcement

XORTX Therapeutics Change of Auditor Signals Strategic Shift Amid Financial Struggles and Leadership Changes,

Published Fri, Jan 17 2025 10:00 PM UTC

XORTX Therapeutics Inc. Announces Change of Auditor Amid Financial Turbulence and Leadership ShakeupCALGARY, Alberta – XORTX Therapeutics Inc. (XORTX or the Company) has taken a significant step as part of its strategic overhaul by announcing a change of auditor. Effective January 16, 2025, the Company has transitioned from Smythe LLP, Chartered Professional Accountants, ...
Management Changes

XORTX Appoints Dr. Michael Bumby as CFO Amid Substantial Financial Losses and Declining ROI

Published Thu, Dec 19 2024 12:00 PM UTC

XORTX Therapeutics Inc. has announced a significant addition to its executive team with the appointment of Dr. Michael Bumby as Chief Financial Officer (CFO). Dr. Bumby s expertise in the pharmaceutical and biotechnology sectors aims to bolster the firm s financial strategy as it navigates a turbulent financial landscape. However, the company has faced harsh realities, with ...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 18.36
Price to Sales (Expected) -
Price to Book 5.25
PEG (TTM) -

Financial Strength Current
Quick Ratio -
Working Capital Ratio -
Leverage Ratio (MRQ) 0.29
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) 0 $
Revenues (TTM) 0.13 $
Cash Flow (TTM) -
Cash 0.18 $
Book Value 0.44 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 39,723
Net Income per Employee (TTM) -
Receivable Turnover Ratio (TTM) 7.43
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.41

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -241.05 %
Net Margin (MRQ) 0 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Xortx Therapeutics Inc's Segments





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.